VT Garraway Absolute Equity Fund I GBP Acc
|United Kingdom of Great Britain and Northern Ireland 0.05%||11.00 %|
|MyCelx Technologies Corp||8.39 %|
|Seri Industrial||7.89 %|
|Cambryn Biologics Plcng||3.32 %|
|Ingenuity Digital Npv||3.32 %|
|Orchard Funding Group PLC||3.15 %|
|PetroTal Corp||2.86 %|
|Moxico Resources P Npv Pl||2.74 %|
|MaxCyte Inc||2.61 %|
|Destiny Pharma PLC||2.52 %|
|United States||37.84 %|
|United Kingdom||23.31 %|
|Basic materials||10.96 %|
|Financial Services||5.46 %|
David manages the City Financial UK Equity Fund. With more than 13 years of investment experience, David joined City Financial in September 2012 having previously worked at Octopus Investments, Hermes Investment Management and M&G Investments. In March 2008 whilst at Octopus, David launched the fund that is now named the City Financial UK Equity Fund. This fund has returned over 90% since launch which compares to a total return from the FTSE All-Share of 35.7%. Whilst at Hermes he co-managed a £500m UK smaller companies portfolio which significantly outperformed the FTSE Small-Cap and AIM benchmark. David graduated from Durham University with a first class honours degree in chemistry.
Data provided by Morningstar.
The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.
This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.
You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.